This company has been marked as potentially delisted and may not be actively trading.

KalVista Pharmaceuticals (KALV) Stock Forecast & Price Target

Get the Latest News and Ratings for KALV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for KalVista Pharmaceuticals and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

KALV Analyst Ratings Over Time

Type	Current Forecast 7/27/25 to 7/27/26	1 Month Ago 6/27/25 to 6/27/26	3 Months Ago 4/28/25 to 4/28/26	1 Year Ago 7/27/24 to 7/27/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	3 Buy rating(s)	7 Buy rating(s)	8 Buy rating(s)
Hold	5 Hold rating(s)	5 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$33.25	$30.60	$32.60	$26.29
Forecasted Upside	23.15% Upside	13.33% Upside	69.44% Upside	80.29% Upside
Consensus Rating	Hold	Hold	Moderate Buy	Buy

KALV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

KALV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

KalVista Pharmaceuticals Stock vs. The Competition

Type	KalVista Pharmaceuticals	Medical Companies	Broader Market
Consensus Rating Score	2.22	2.29	2.52
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	23.15% Upside	974.37% Upside	14.30% Upside
News Sentiment Rating	Neutral News See Recent KALV News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
5/1/2026	HC Wainwright 4 of 5 stars	Andrew S. Fein Not Rated	Downgrade	Buy ➝ Neutral	$37.00 ➝ $27.00	+1.28%
4/30/2026	JonesTrading 3 of 5 stars		Downgrade	Strong-Buy ➝ Hold
4/30/2026	Needham & Company LLC 4 of 5 stars	Serge Belanger 4 of 5 stars	Downgrade	Buy ➝ Hold
4/29/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
4/29/2026	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jonathan Wolleben Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/21/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Sell (D-)
3/26/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Paul Matteis Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$39.00 ➝ $42.00	+140.18%
12/3/2025	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
11/11/2025	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Market Outperform
12/18/2024	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Buy	$22.00	+154.34%
Get the Latest News and Ratings for KALV and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for KalVista Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
12/9/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Pete Stavropoulos Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 07:17 AM ET.

KALV Forecast - Frequently Asked Questions

According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for KalVista Pharmaceuticals is $33.25, with a high forecast of $42.00 and a low forecast of $27.00.

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for KalVista Pharmaceuticals in the last year. There is currently 1 sell rating, 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" KALV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KALV, but not buy additional shares or sell existing shares.

According to analysts, KalVista Pharmaceuticals's stock has a predicted upside of 23.15% based on their 12-month stock forecasts.

Over the previous 90 days, KalVista Pharmaceuticals's stock had 5 downgrades by analysts.

KalVista Pharmaceuticals has been rated by research analysts at Citizens Jmp, HC Wainwright, JonesTrading, Leerink Partners, and Needham & Company LLC in the past 90 days.

Analysts like KalVista Pharmaceuticals less than other "medical" companies. The consensus rating score for KalVista Pharmaceuticals is 2.22 while the average consensus rating score for "medical" companies is 2.29. Learn more on how KALV compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With KalVista Pharmaceuticals Recommendations

This page (NASDAQ:KALV) was last updated on 7/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.